secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atea Pharmaceuticals, Inc. (AVIR)
CIK:        0001593899
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001193125-25-032826
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atea Pharmaceuticals appoints Arthur Kirsch to Board of Directors
-----------------------------------------------------------------

- Arthur Kirsch, age 73, elected as Class I director effective February 20, 2025.
- Kirsch brings experience as Senior Advisor at Alvarez & Marsal Life Sciences Industry Group.
- Annual cash retainer of $45,000 plus initial option to purchase 164,800 shares vesting over 36 months.
- Kirsch currently serves on board of Liquidia Technologies (LQDA); previously on boards of Kadmon, Immunomedics, POZEN, Aralez.
- Compensation follows Non-Employee Director Compensation Program disclosed in Q2 2024 Form 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525032826/0001193125-25-032826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1593899/000119312525032826/d918567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-032826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer